• FibroGen China
  • Newsroom
  • Contact
  • About Us
    • Our Company
    • Our Strategy
    • FibroGen China
    • Executive Team
    • Board of Directors
    • Our Partners
    • In Memoriam
    • Contact Us
  • Focus Areas
    • Our Expertise
    • Anemia
    • Idiopathic Pulmonary Fibrosis
    • Pancreatic Cancer
    • Duchenne Muscular Dystrophy
    • Corneal Blindness
    • Publications
  • Pipeline
    • R&D Pipeline
    • Roxadustat
    • Pamrevlumab
    • FG-5200
  • Clinical Trials
    • Our Priorities
    • Roxadustat Trials
    • Pamrevlumab Trials
  • Careers
    • Our Culture
    • Career Opportunities
    • Notice to Recruiters
  • Investors and Media
    • Investor Overview
    • Stock Information
      • Stock Quote
      • Stock Chart
      • Historical Price Lookup
      • Analyst Coverage
    • Press Releases
    • Events and Presentations
    • Corporate Governance
      • Documents & Charters
      • Committee Composition
      • Contact the Board
    • SEC Filings
    • Financial Information
    • Shareholder Services
    • Investor FAQs
MENU MENU
close x
  • About Us
    • Our Company
    • Our Strategy
    • FibroGen China
    • Executive Team
    • Board of Directors
    • Our Partners
    • In Memoriam
    • Contact Us
  • Focus Areas
    • Our Expertise
    • Anemia
    • Idiopathic Pulmonary Fibrosis
    • Pancreatic Cancer
    • Duchenne Muscular Dystrophy
    • Corneal Blindness
    • Publications
  • Pipeline
    • R&D Pipeline
    • Roxadustat
    • Pamrevlumab
    • FG-5200
  • Clinical Trials
    • Our Priorities
    • Roxadustat Trials
    • Pamrevlumab Trials
  • Careers
    • Our Culture
    • Career Opportunities
    • Notice to Recruiters
  • Investors and Media
    • Investor Overview
    • Stock Information
      • Stock Quote
      • Stock Chart
      • Historical Price Lookup
      • Analyst Coverage
    • Press Releases
    • Events and Presentations
    • Corporate Governance
      • Documents & Charters
      • Committee Composition
      • Contact the Board
    • SEC Filings
    • Financial Information
    • Shareholder Services
    • Investor FAQs
  • FibroGen China
  • Newsroom
  • Contact

Leadership

  • About Us
    • Our Company
    • Our Strategy
    • FibroGen China
    • Executive Team
    • Board of Directors
    • Our Partners
    • In Memoriam
    • Contact Us
  • Focus Areas
    • Our Expertise
    • Anemia
    • Idiopathic Pulmonary Fibrosis
    • Pancreatic Cancer
    • Duchenne Muscular Dystrophy
    • Corneal Blindness
    • Publications
  • Pipeline
    • R&D Pipeline
    • Roxadustat
    • Pamrevlumab
    • FG-5200
  • Clinical Trials
    • Our Priorities
    • Roxadustat Trials
    • Pamrevlumab Trials
  • Careers
    • Our Culture
    • Career Opportunities
    • Notice to Recruiters
  • Investor & Media
    • Investor Overview
    • Stock Information
    • Press Releases
    • Events and Presentations
    • Corporate Governance
    • SEC Filings
    • Financial Information
    • Shareholder Services
    • Investor FAQs
  • Terms of Use
  • Privacy Notice
  • About Us
  • Focus Area
  • Pipeline
  • Clinical Trials
  • Investors and Media
  • Terms of Use
  • Privacy Notice
  • Copyright © 2019 FibroGen, Inc.
  • 409 Illinois Street, San Francisco, CA 94158